Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion

The Food and Drug Administration issued guidance for evaluating the cardiovascular risk of new diabetes mellitus drugs in 2008. Accumulating evidence from several completed trials conducted within this framework raises questions as to whether requiring safety outcome studies for all new diabetes mel...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Eur Heart J Cardiovasc Pharmacother
Prif Awduron: Zannad, Faiez, Stough, Wendy Gattis, Lipicky, Raymond J., Tamargo, Juan, Bakris, George L., Borer, Jeffrey S., Alonso García, Maria de los Angeles, Hadjadj, Samy, Koenig, Wolfgang, Kupfer, Stuart, McCullough, Peter A., Mosenzon, Ofri, Pocock, Stuart, Scheen, André J., Sourij, Harald, Van der Schueren, Bart, Stahre, Christina, White, William B., Calvo, Gonzalo
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2016
Pynciau:
Reviews
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4907355/
https://ncbi.nlm.nih.gov/pubmed/27418973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ehjcvp/pvw007
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg